Mylan CEO defends EpiPen price hike in congressional hearing

Heather Bresch.
(Image credit: Alex Wong/Getty Images)

The fight over the price of the EpiPen, an emergency treatment device for severe allergic reactions, has officially reached Capitol Hill. CEO Heather Bresch of Mylan, the company that makes the EpiPen, defended the drug's drastic price increase during a congressional hearing Wednesday as a balance between "price and access," pointing out that Mylan only profits $50 for each two-pack sold and that it has in the past distributed EpiPens to schools for free.

"Looking back, I wish we had better anticipated the magnitude and acceleration of the rising financial issues for a growing minority of patients, who may have ended up paying the [list price] or more. We never intended this," Bresch said in a statement released ahead of the hearing.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us